Muutke küpsiste eelistusi

E-raamat: Real-World Evidence Generation and Evaluation of Therapeutics: Proceedings of a Workshop

  • Formaat: 102 pages
  • Ilmumisaeg: 05-Jul-2017
  • Kirjastus: National Academies Press
  • Keel: eng
  • ISBN-13: 9780309455633
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 4,08 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: 102 pages
  • Ilmumisaeg: 05-Jul-2017
  • Kirjastus: National Academies Press
  • Keel: eng
  • ISBN-13: 9780309455633
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

The volume and complexity of information about individual patients is greatly increasing with use of electronic records and personal devices. Potential effects on medical product development in the context of this wealth of real-world data could be numerous and varied, ranging from the ability to determine both large-scale and patient-specific effects of treatments to the ability to assess how therapeutics affect patients' lives through measurement of lifestyle changes.





In October 2016, the National Academies of Sciences, Engineering, and Medicine held a workshop to facilitate dialogue among stakeholders about the opportunities and challenges for incorporating real-world evidence into all stages in the process for the generation and evaluation of therapeutics. Participants explored unmet stakeholder needs and opportunities to generate new kinds of evidence that meet those needs. This publication summarizes the presentations and discussions from the workshop.

Table of Contents



Front Matter 1 Introduction 2 Improving Evidence Generation for Decision Making on Approval and Use of New Treatments: Some Stakeholder Priorities 3 Opportunities for Real-World Data 4 Generating and Incorporating Real-World Evidence into Medical Product Development and Evaluation: Building from Successful Case Studies 5 Potential Strategies for a Way Forward Appendix A: Bibliography Appendix B: Workshop Agenda Appendix C: Participant Biographies Appendix D: Discussion Paper: Real-World Evidence to Guide theApproval and Use of New Treatments
Acronyms and Abbreviations xv
1 Introduction
1(6)
Organization of the Proceedings of a Workshop
5(2)
2 Improving Evidence Generation For Decision Making On Approval And Use Of New Treatments: Some Stakeholder Priorities
7(10)
The Current Landscape for Evidence Generation Processes
8(1)
Stakeholder Perspectives on Priorities for Improving Real-World Decision Making
9(6)
Potential Crosscutting Priorities for Improving Real-World Decision Making
15(2)
3 Opportunities For Real-World Data
17(10)
Leveraging Electronic Health Records
18(2)
The Power of Linking and Mining Disparate Data Sources
20(3)
Collecting Real-World Data Outside the Clinical Setting Using Digital Health Tools
23(1)
Considerations for Realizing the Potential of Real-World Data
24(3)
4 Generating And Incorporating Real-World Evidence Into Medical Product Development And Evaluation: Building From Successful Case Studies
27(12)
Randomization in the Clinical Setting
28(2)
Research Embedded in Registries
30(3)
Population-Based Surveillance Using Health System Data
33(6)
5 Potential Strategies for a Way Forward
39(12)
Data Availability
40(3)
Study Design, Data Methods, and Data Quality
43(2)
Incentives
45(3)
Some Practical Next Steps
48(3)
APPENDIXES
A Bibliography
51(2)
B Workshop Agenda
53(8)
C Participant Biographies
61(16)
D Discussion Paper: Real-World Evidence to Guide the Approval and Use of New Treatments
77